< Back to search
Filter
1

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for
Classic Follicular Lymphoma,
Location: Providence RI, Lebanon NH, Long Branch NJ,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

for
Viral Associated Malignancies, Kaposi Sarcoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT04902443

Phase1, Recruiting

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

for
T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06698003

Phase2, Recruiting

Personalized NK Cell Therapy in CBT

for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 15 - 70+

Code: NCT02727803

Phase2, Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for
B-cell Acute Lymphoblastic Leukemia,
Location: Boston MA, New Haven CT, Valhalla NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 25

Code: NCT06395103

Phase1, Phase2, Recruiting

Interested in new lymphoma trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Saint John, Damariscotta ME, Brunswick ME, Augusta ME,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04269902

Phase3, Recruiting

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

for
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Location: West Valley City UT
Sponsor: Lantern Pharma Inc.

Sex: All

Age: 18+

Code: NCT06132503

Phase1, Recruiting

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

for
Diffuse Large B-cell Lymphoma,
Location: Richmond VA
Sponsor: Virginia Commonwealth University

Sex: All

Age: 18+

Code: NCT06846463

Phase2, Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Location: Halifax, Bangor ME, Bath ME, Portland ME,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 5 - 60

Code: NCT05675410

Phase3, Recruiting

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

for
Lymphoma, B-Cell, Lymphoma, Large-cell Lymphoma,
Location: New York NY
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05940272

Recruiting

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

for
Diffuse Large B Cell Lymphoma (DLBCL)
Location: Montreal, Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT06050694

Phase2, Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for
Mantle Cell Lymphoma
Location: Chicago IL, Providence RI, Westerly RI, Waterford CT,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 60+

Code: NCT05976763

Phase3, Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Location: Augusta ME, Brewer ME, Rockport ME, Belfast ME,
Sponsor: American Society of Clinical Oncology

Sex: All

Age: 12+

Code: NCT02693535

Phase2, Recruiting

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

for
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT06784167

Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for
Breast Carcinoma, Colorectal Carcinoma,
Location: Rockport ME, Belfast ME, Brunswick ME, Augusta ME,
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18+

Code: NCT06418204

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

for
Hodgkin Lymphoma
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06377566

Phase2, Recruiting

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

for
Cutaneous T-Cell Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06698822

Phase2, Recruiting

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

for
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia,
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 0 - 70+

Code: NCT01853631

Phase1, Recruiting

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

for
Peripheral T Cell Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06630091

Phase2, Recruiting

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

for
Primary Central Nervous System Lymphoma, Recurrent Cancer,
Location: Boston MA, New York NY
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04421560

Phase1, Phase2, Recruiting